What Should I Do If My Depression Treatment Isn’t Working?

What should I do if my antidepressant is not helping?

Ask for a treatment review with the clinician who manages your care. The aim is to understand what “not helping” means: no change, some improvement without remission, a side effect that makes treatment hard to continue, or symptoms that have worsened.

Bring a clear account of what you have taken, how consistently you have taken it, how long you have taken it, and what changed. Include side effects and any changes in sleep, appetite, concentration, or mood. According to NIMH’s depression guidance, some symptoms, such as sleep, appetite, and concentration, can improve before mood does.

The clinician can assess whether the trial was adequate and whether the diagnosis or treatment plan needs another look. The VA/DoD guideline describes an initial medication trial for its next-step recommendations as maximized monotherapy for at least 4–6 weeks. That is a guideline threshold for clinical review, not an instruction to change a dose on your own.

After partial or no response to an adequate initial trial, the VA/DoD guideline lists switching to another antidepressant, switching to psychotherapy, adding psychotherapy, or adding a second-generation antipsychotic. These are clinician-guided options, not a single sequence that fits everyone. The choice depends on the response so far, tolerability, and the treatment plan worked out with the clinician.

After a medication starts or changes, the VA/DoD guideline recommends monitoring at least monthly, including symptoms, adherence, and adverse effects. Follow-up gives the clinician a way to see whether the next step is helping and whether problems are getting in the way.

How long should I wait before saying depression medication isn't working?

There is no single waiting period that answers every case, but antidepressants usually take 4–8 weeks to work, according to NIMH. Improvement in sleep, appetite, or concentration can come before a lift in mood, so a review should look at several symptoms rather than mood alone.

The VA/DoD guideline’s summary uses at least 4–6 weeks of maximized monotherapy as the definition of an adequate initial medication trial for the options it describes. This timing differs in purpose from NIMH’s general statement: one explains when medicines usually take effect, while the other sets a threshold for considering next steps in that guideline.

A calendar alone does not establish whether a trial was adequate. The clinician also needs to know whether the medication was taken consistently, whether side effects interrupted treatment, and whether symptoms changed. If side effects are severe or symptoms worsen, contact the treating clinician rather than waiting for a target date or stopping medication without guidance.

Prepare for the appointment by writing down the treatment and approximate start and stop dates, missed doses, benefits, side effects, and the symptoms that still affect daily life. This turns “it didn’t work” into information the clinician can use to compare the next options.

Does trying two antidepressants mean I have treatment-resistant depression?

Not by itself; the adequacy of the trials matters. NIMH describes treatment-resistant depression as depression that does not get better after trying at least two antidepressants, while the VA/DoD guideline frames later options around adequate medication trials.

The phrase describes a treatment response, not a personal failure and not proof that no treatment remains. NIMH’s background on the STAR*D study explains that people who did not reach remission or could not tolerate side effects could move to later treatment steps, including switching or augmenting treatment with medication or talk therapy.

STAR*D studied more than 4,000 adult outpatients, ages 18–75, according to NIMH. In a report on the study, Rush and colleagues found remission rates across four successive steps of 36.8%, 30.6%, 13.7%, and 13.0%, with a cumulative remission rate of 67%. These study figures describe groups in that research; they do not predict what will happen for one person.

The pattern matters: later steps helped some participants, even as remission rates within each successive step were lower. The researchers also reported higher relapse rates during follow-up among participants who needed more treatment steps, which supports ongoing monitoring rather than treating a new plan as a finished process.

When several adequate trials have not helped enough, the VA/DoD guideline suggests offering repetitive transcranial magnetic stimulation after partial or no response to two or more adequate medication trials. It says ketamine or esketamine may be considered after several adequate trials. NIMH says brain-stimulation treatments are generally considered after other treatments and should be prescribed and monitored by a suitably trained health care provider.

NIMH notes that electroconvulsive therapy may be considered for severe treatment-resistant depression or when a rapid response is needed in life-threatening circumstances. Its brain-stimulation guidance says ECT usually takes effect within the first week of treatment. A plan involving brain stimulation usually also includes psychotherapy, medication, or both; other treatment should not be stopped unless a provider advises it.